Innovations in Small Interfering RNA (siRNA) Therapy

Leading experts highlight the established role of PCSK9 inhibitors, such as evolocumab and alirocumab, and introduce the promising second-generation PCSK9 inhibitors, known as small interfering RNA (siRNA), which represent an innovative therapeutic approach that selectively reduces the production of specific proteins through RNA interference.

Related Content:

Optimizing Cardiovascular Health: Advancements in LDL Cholesterol Management through Intensive and Early Treatment StrategiesIcahn School of Medicine at Mount SinaiClinicalCardiologyPeer ExchangeVideo Series

PEGylated Uricase Well-Tolerated, Demonstrates Dose-Dependent Urate-Lowering

Educational Video Use in Shared Decision-Making Improves Literacy About Psoriasis

AHA Guidelines and Patient Mortality